Investigating the neuroprotective effect of Copolymer‐1 in acute primary angle closure – Interim report of a randomized placebo‐controlled double‐masked clinical trial

To investigate the neuroprotective effect of Copolymer‐1 (Cop‐1) in patients with acute primary angle closure (APAC) in a randomized double‐masked controlled trial.

• Publication year

  2019

• Venue

  Acta ophthalmologica

• Publication date

  2019-03-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/aos.14099PMID 30916898
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Two decades of glatiramer acetate: From initial discovery to the current development of generics.

  2017cited by this paper
• Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis.

  2014cited by this paper
• Examination of the performance of different pointwise linear regression progression criteria to detect glaucomatous visual field change

  2012cited by this paper
• Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis

  2011cited by this paper
• Neuroprotection and progenitor cell renewal in the injured adult murine retina requires healing monocyte-derived macrophages

  2011cited by this paper
• B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.

  2010cited by this paper
• Therapeutic Induction of Regulatory, Cytotoxic CD8+ T Cells in Multiple Sclerosis1

  2006cited by this paper
• The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice.

  2005cited by this paper
• Changes in retinal nerve fiber layer thickness after acute primary angle closure.

  2004influential reference
• Neurodegeneration and neuroprotection in glaucoma: development of a therapeutic neuroprotective vaccine: the Friedenwald lecture.

  2003cited by this paper
• Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure

  2003cited by this paper
• Identification of progressive glaucomatous visual field loss.

  2002cited by this paper
• Degeneracy, as opposed to specificity, in immunotherapy.

  2002cited by this paper
• Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma

  2001cited by this paper
• European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

  2001cited by this paper
• The visual field following acute primary angle closure.

  2001cited by this paper
• Angle-Closure Glaucoma in an Urban Population in Southern India

  2001cited by this paper
• Angle-closure glaucoma in an urban population in southern India. The Andhra Pradesh eye disease study.

  2000cited by this paper
• The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district.

  2000cited by this paper
• Meta-Analysis of Clinical Trials with Copolymer 1 in Multiple Sclerosis

  2000cited by this paper
• T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.

  2000cited by this paper
• The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients.

  1999cited by this paper
• Glaucoma in Mongolia. A population-based survey in Hövsgöl province, northern Mongolia.

  1996cited by this paper
• Analysis of visual field progression in glaucoma.

  1996cited by this paper
• Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability.

  1994cited by this paper
• Issues in the epidemiology and population-based screening of primary angle-closure glaucoma.

  1992cited by this paper
• The prevalence of glaucoma.

  1981cited by this paper

• Eye-brain axis: the crosstalk between neurons and immune cells

  2026cites this paper
• Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation

  2022cites this paper
• T Cell-Mediated Autoimmunity in Glaucoma Neurodegeneration

  2021cites this paper
• Experimental simulation analysis for single phase transformer tests

  2020cites this paper
• Innovative IOP-Independent Neuroprotection and Neuroregeneration Strategies in the Pipeline for Glaucoma

  2020cites this paper